MilliporeSigma Collaborates with LabCentral to Foster Biotech Startups
- Company to provide expert guidance and counsel to biotechstartups
- New sponsorship to offer access to state-of-the-art collaborativelaboratory
Billerica, Massachusetts, April 25, 2017 — MilliporeSigma announced today that the company will sponsor the Startup Program at LabCentral, a biotechnology incubator, in Cambridge, Massachusetts. LabCentral is a private, non-profit organization that provides entrepreneurs and innovative life-sciences startups with lab space and resources to nurture the next generation of biotech companies. It comprises approximately 125 scientists and entrepreneurs.
MilliporeSigma’s collaboration with LabCentral, like its ongoing Emerging Biotech grant program, gives biotech startups access to process development tools, education programs and training to support their success and strengthen the biotech community.
“Innovation is at the heart of the life science industry and startups play an important role in developing new and often life-changing, scientific discoveries,” said Udit Batra, member of the Executive Board, Merck KGaA, Darmstadt Germany and CEO, MilliporeSigma. “We are collaborating with LabCentral to be a resource for these emerging companies and to help them get the best start possible.”
As a sponsor of the LabCentral Startup Program, MilliporeSigma will “adopt” a startup company which entitles the selected company to a priority spot and one-year prepaid lab bench in LabCentral’s shared laboratory workspace. Candidates can consult program rules and submit their application at emdmillipore.com/startup-program. Submission close is July 2, 2017.
“This is an exciting time at LabCentral as we begin construction on our facility expansion, which will make room for an additional 30 startups,” said LabCentral Co-Founder and President Johannes Fruehauf, M.D., Ph.D. “Today, LabCentral has become the de facto standard in co-working facilities for biotech startups. From the breadth and quality of our infrastructure and equipment, to our supportive services and programming, to the LabCentral Startup Program—our sponsors are critical partners. We are thrilled to welcome MilliporeSigma as a Gold sponsor, and look forward to a fruitful collaboration with the technical team.”
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck KGaA, Darmstadt, Germany, generated sales of € 15.0 billion in 66 countries.
Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the „Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Merck KGaA today shared updates on the company’s healthcare research and development strategy, aimed at doubling R&D productivity.